Skip to Content
Merck
  • Mislocalization of protein kinase A drives pathology in Cushing's syndrome.

Mislocalization of protein kinase A drives pathology in Cushing's syndrome.

Cell reports (2022-07-14)
Mitchell H Omar, Dominic P Byrne, Kiana N Jones, Tyler M Lakey, Kerrie B Collins, Kyung-Soon Lee, Leonard A Daly, Katherine A Forbush, Ho-Tak Lau, Martin Golkowski, G Stanley McKnight, David T Breault, Anne-Marie Lefrançois-Martinez, Antoine Martinez, Claire E Eyers, Geoffrey S Baird, Shao-En Ong, F Donelson Smith, Patrick A Eyers, John D Scott
ABSTRACT

Mutations in the catalytic subunit of protein kinase A (PKAc) drive the stress hormone disorder adrenal Cushing's syndrome. We define mechanisms of action for the PKAc-L205R and W196R variants. Proximity proteomic techniques demonstrate that both Cushing's mutants are excluded from A kinase-anchoring protein (AKAP)-signaling islands, whereas live-cell photoactivation microscopy reveals that these kinase mutants indiscriminately diffuse throughout the cell. Only cAMP analog drugs that displace native PKAc from AKAPs enhance cortisol release. Rescue experiments that incorporate PKAc mutants into AKAP complexes abolish cortisol overproduction, indicating that kinase anchoring restores normal endocrine function. Analyses of adrenal-specific PKAc-W196R knockin mice and Cushing's syndrome patient tissue reveal defective signaling mechanisms of the disease. Surprisingly each Cushing's mutant engages a different mitogenic-signaling pathway, with upregulation of YAP/TAZ by PKAc-L205R and ERK kinase activation by PKAc-W196R. Thus, aberrant spatiotemporal regulation of each Cushing's variant promotes the transmission of distinct downstream pathogenic signals.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3-Isobutyl-1-methylxanthine, ≥99%, BioUltra
Sigma-Aldrich
Adrenocorticotropic Hormone human, ≥97% (HPLC)
Sigma-Aldrich
Isopropyl β-D-1-thiogalactopyranoside, ≥99% (TLC)